Logo newsbot.ch

Wirtschaft

Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress

2019-09-23 07:20:16
newsbot by content-proivder.ch GmbH
Quelle:

"We are excited to present a number of key datasets across a broad range of diseases at ESMO this year, including results from our Tecentriq combination study in people with previously untreated advanced bladder cancer, the first positive Phase III cancer immunotherapy trial in this setting, wie die Roche mitteilt.

In addition, we will present data from our Phase III Tecentriq monotherapy study in previously untreated advanced lung cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “We will also share data from a study using Foundation Medicine’s liquid (blood) biopsy, a more patient-friendly approach to diagnosing and treating cancer.

The results of the first cohort of this study involving ALK+ non-small cell lung cancer patients who received Alecensa will be presented at the congress.”IMvigor130 met its co-primary endpoint of progression-free survival (PFS). The combination showed a statistically significant reduction in the risk of disease worsening or death in people with previously untreated locally advanced or metastatic urothelial carcinoma (mUC).

Encouraging overall survival (OS) results were observed at this interim analysis, however these results are not yet mature. The study represents the first positive Phase III immunotherapy combination study in patients with previously untreated bladder cancer.

Tecentriq monotherapy was the first cancer immunotherapy approved in bladder cancer.In addition, updated OS results from the IMpower133 study will also be presented at ESMO. IMpower133 showed that first-line Tecentriq in combination with chemotherapy helped people with extensive-stage small cell lung cancer (ES-SCLC) live significantly longer compared with chemotherapy alone.

This updated data presentation will also feature analysis by PD-L1 subgroup.Featured in the official ESMO press programme at 08:30 on 28 September will be a retrospective analysis using comprehensive genomic profiling (CGP) of carcinoma of unknown primary origin (CUP) patients that investigated eligibility for molecularly guided targeted or immunotherapy treatment options in the CUPISCO study design. To make that determination, archival tissue from centrally reviewed CUP cases was subjected to CGP using the FoundationOne® CDx test.

CUPISCO is a Phase II, randomised, active-controlled, multi-centre study comparing the efficacy and safety of targeted therapy or cancer immunotherapy guided by genomic profiling versus platinum-based chemotherapy in patients with a CUP site.Roche has been working to transform cancer care for more than 50 years, bringing the first specifically designed anti-cancer chemotherapy drug, fluorouracil, to patients in 1962. Roche’s commitment to developing innovative medicines and diagnostics for cancers remains steadfast. The Roche Group’s portfolio of innovative cancer medicines includes: Alecensa® (alectinib); Avastin® (bevacizumab); Cotellic® (cobimetinib); Erivedge® (vismodegib); Gazyva®/Gazyvaro® (obinutuzumab); Herceptin® (trastuzumab); Kadcyla® (trastuzumab emtansine); MabThera®/Rituxan® (rituximab); Perjeta® (pertuzumab); Polivy® (polatuzumab vedotin-piiq); Tarceva® (erlotinib); RozlytrekTM (entrectinib); Tecentriq® (atezolizumab); Venclexta®/Venclyxto® (venetoclax); Xeloda® (capecitabine); Zelboraf® (vemurafenib).

Furthermore, the Roche Group has a robust investigational oncology pipeline focusing on new therapeutic targets and novel combination strategies. For more information on Roche’s approach to cancer, visit www.roche.com.Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society.

The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines.

Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com..

Suche nach Stichworten:

Roche present data its broad oncology portfolio European Society Medical Oncology 2019 Congress